ESG performance in the pharmaceutical and biotechnology sector in 2024

This report provides a detailed analysis of the sustainability performance of 86 European companies in the Pharmaceutical and Biotechnology sector, based on EthiFinance's ESG Ratings assessment conducted in 2024 with data for fiscal year 2023. The study highlights key trends and findings on the sector's most important aspects in the four pillars of sustainability: Environmental, Social, Governance and External Stakeholders; and provides information on the sector's progress and challenges in terms of sustainable practices.